CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Axicabtagene Ciloleucel
Related studies linked through entity extraction aliases.
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
- Status
- RECRUITING
- Phase
- PHASE3
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Status
- RECRUITING
- Phase
- PHASE3
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
- Status
- RECRUITING
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
Emapalumab Prevention of CAR-T Cell Associated Toxicities
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Status
- AVAILABLE
- Phase
- N/A
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
- Status
- COMPLETED
- Phase
- PHASE4
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- Status
- COMPLETED
- Phase
- PHASE1